The European Commission (EC) has granted marketing authorisation for Eli Lilly’s Kisunla (donanemab), a treatment for early symptomatic Alzheimer’s disease (AD). AD affects nearly 7 million people in Europe and is characterised by progressive cognitive decline, including memory loss and impaired thinking. Kisunla, administered via infusion, works by targeting and clearing this build-up, with the aim of preserving cognitive function and slowing disease progression. The EC marketing authorisation was supported by data from the phase 3 TRAILBLAZER-ALZ 2 trial, which showed Kisunla significantly slowed cognitive and functional decline compared with placebo. Following the EC marketing authorisation, Kisunla can now be prescribed across the EU for adults with mild cognitive impairment or mild dementia stages of AD, with confirmed amyloid pathology, who are apolipoprotein E (ApoE4) heterozygotes or non-carriers.